Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine Doses in Adductor Canal Block for TKA
NCT06740214Phase 3Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bupivacaine in postoperative pain (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Weighted area under curve (AUC) pain score at 48 hours. Started Sep 2025; status: recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06740214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740214.